Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) EBITDA (2016 - 2026)

Ovid Therapeutics filings provide 11 years of EBITDA readings, the most recent being -$17.8 million for Q1 2026.

  • Quarterly EBITDA fell 42.2% to -$17.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$47.7 million through Mar 2026, up 16.28% year-over-year, with the annual reading at -$42.4 million for FY2025, 31.42% up from the prior year.
  • EBITDA hit -$17.8 million in Q1 2026 for Ovid Therapeutics, down from -$12.3 million in the prior quarter.
  • Across five years, EBITDA topped out at -$5.1 million in Q2 2025 and bottomed at -$20.5 million in Q2 2024.
  • Average EBITDA over 5 years is -$13.9 million, with a median of -$13.2 million recorded in 2024.
  • The largest annual shift saw EBITDA tumbled 109.21% in 2022 before it surged 75.27% in 2025.
  • Ovid Therapeutics' EBITDA stood at -$12.2 million in 2022, then tumbled by 49.41% to -$18.2 million in 2023, then skyrocketed by 41.05% to -$10.7 million in 2024, then decreased by 14.65% to -$12.3 million in 2025, then plummeted by 45.17% to -$17.8 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's EBITDA are -$17.8 million (Q1 2026), -$12.3 million (Q4 2025), and -$12.5 million (Q3 2025).